As of today (2024-05-15), the Forward Annual Dividend Yield of Gamida Cell is 0.00%.
As of today (2024-05-15), the Trailing Annual Dividend Yield of Gamida Cell is 0.00%.
GMDAQ's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.55 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Gamida Cell's Forward Dividend Yield %
For the Biotechnology subindustry, Gamida Cell's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gamida Cell's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Forward Dividend Yield % falls into.
Gamida Cell Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gamida Cell Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Gamida Cell's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your